Valensa International has announced the launch of a new ingredient, Serevelle, for hair health.
The Floridian company's newest offering is a proprietary, patented bioactive fatty acid ingredient derived from saw palmetto, designed to promote healthy hair.
The company states it is also backed by two newly published human clinical studies in women and men with thinning hair.
Serevelle is made with Valensa's patented ActiLipid4Hair technology that yields the highest concentration of the four most bioactive free fatty acids from saw palmetto (Serenoa repens).
Valensa also said that the new ingredient is the nutricosmetic industry's only 3-in-1 hair-health ingredient, suppressing hair loss, promoting hair growth and improving overall hair health in men and women.
Key outcomes from the clinical study include the following:
- At 90 days, participants saw a 12.8 times greater increase in hair density and fuller scalp coverage, a 7.8 times greater increase in healthy, thicker hairs and six times more new hair growth and follicle reactivation
- At 180 days, participants saw a four-times increase in healthy, thicker hairs, a five-times increase in new hair growth and follicle reactivation and a four-times increase in visibly denser, fuller scalp coverage
- Additional outcomes at 180 days included a five-fold improvement in the sum of hair width and a three-fold improvement in the increase of follicular units.
In menopausal women, the study also showed several key outcomes (compared with placebo). Results also showed that Serevelle increased the number of active hair follicles, provided twice the new hair growth in problematic areas and led to a four-fold increase in healthy, thicker hairs and a three-fold increase in hair density and scalp coverage.
A similar subgroup analysis in men showed statistically significant hair growth across all hair types.
Overall, after 180 days, the Serevelle participants showed a 40% incremental improvement, resulting in four-times denser hair and scalp coverage.
Dr Ablon commented: "These subgroup findings point to the potential for differentiated solutions tailored to menopausal women and men, all anchored in the same core ingredient and dose."
In pre-clinical research, Serevelle showed 75-fold potent inhibition of 5 alpha reductase, an enzyme largely responsible for hair loss and thinning, compared to a
standard saw palmetto extract.
The ingredient also showed multi-mechanistic benefits that resulted in prolonging the anagen (growth) phase by 30% and supports a healthy follicle environment by reducing inflammatory stress and maintaining stem cell niche.
Serevelle addresses unmet consumer needs with low micro-doses and an efficient cost-per-dose.
"Recent market research data forecasts the global nutricosmetic market will experience a robust 7.5% CAGR through 2034," stated Umasudhan (Uma) Palaniswamy, Valensa International CEO.
According to Valensa, the hair loss and hair growth supplement market is underserved and consumers are dissatisfied with large doses, ineffective products and safety issues.
Also, no ingredient has undergone robust clinical studies demonstrating efficacy in men and women across all life stages, including the menopausal stage.
The clinical low dose of 105 mg of ActiLipid4Hair can be delivered cost-effectively in formats such as softgels, capsules, tablets, gummies, powder beverage mixes and emulsions. Serevelle is also available as a topical serum.